From 3 to 5 February in Cambridge (UK) will host an international conference «Biomarkers for Brain Disorders: Challenges and Opportunities».
This is the 2nd Trust Scientific Conference on Biomarkers for Brain Disorders: Challenges and Opportunities. This conference will once again bring together leading neuroscientists from academia and industry involved in genomics, proteomics, diagnostics, imaging and regulatory affairs.
The discovery and validation of biomarkers in neurological and neurodegenerative diseases is an important challenge for early diagnosis of disease and for the development of therapeutics. Methodological and regulatory aspects of biomarker 
identification and qualification across a wide spectrum of neurodevelopmental, neurodegenerative and neuropsychiatric diseases will be discussed including, autism, Parkinson's disease, Alzheimer’s disease, multiple sclerosis and schizophrenia. There will also be a series of break-out sessions for in-depth discussion on the standardization of clinical biomarkers most likely to aid diagnosis and imaging-based studies in biomarker drug discovery. This meeting provides an opportunity for scientists from academia and the commercial sector to discuss the current ‘state of the art’ in biomarkers and will aid future investment decisions in both sectors.
Session Titles:
- Neuropsychiatric disorders
- Neurological disease
- Neurodegenerative diseases
- Neurodevelopmental biomarkers and targets
- Standardization of clinical biomarkers
- Imaging-based studies in biomarker drug discovery
For more information, see https://registration.hinxton.wellcome.ac.uk/display_info.asp?id=303